Positive CHMP opinions for AstraZeneca and Novartis, but suspension of Octapharma's Octagam called for; Roche Avastin review

26 September 2010

Meeting highlights from the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) last week included good news for Anglo-Swedish drug maker AstraZeneca (LSE: ANZ) and Swiss major Novartis (NOVN: VX) but, as reported last Friday, not for GlaxoSmithKline, with the Agency calling for the suspension of its once blockbuster diabetes drug Avandia (rosiglitazone) and a negative take on Merck KGaA’s cladribine for multiple sclerosis, which caused the latter’s share price to tumble near 10% (The Pharma Letter September 24).

Positive opinion for new medicines adopted

The Committee adopted positive opinions recommending the granting of marketing authorizations for the following new medicines:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK